XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)
1 Months Ended 3 Months Ended 6 Months Ended
Sep. 28, 2016
USD ($)
Agreement
$ / shares
shares
Nov. 30, 2016
USD ($)
Sep. 30, 2016
USD ($)
Mar. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
Mar. 31, 2017
USD ($)
Mar. 31, 2018
USD ($)
$ / shares
Mar. 31, 2017
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Stock issued, price per share | $ / shares       $ 5.25     $ 5.25  
Proceeds from the issuance of common stock             $ 56,585,035 $ 12,691,937
Collaboration and License agreements | Amgen                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Agreement date Sep. 28, 2016              
Number of agreements | Agreement 2              
ARO-AMG1 Agreement | Amgen                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Additional amount of common stock shares agreed to sell upon exercise of option $ 5,000,000              
Number of trading days, used to calculate share price of Common Stock, surrounding option exercise date 30 days              
Cash received as due under collaboration agreement     $ 5,000,000          
Deferred revenue     $ 5,000,000 $ 1,300,000     1,300,000  
Deferred revenue amortized into revenue       600,000   $ 600,000 1,300,000 1,300,000
Collaboration and License agreements | Maximum                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Option payments, and development, regulatory and sales milestone payments. $ 617,000,000              
Collaboration and License agreements | Amgen                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Cash received as due under collaboration agreement 35,000,000              
Proceeds from the issuance of common stock $ 21,500,000              
ARO-LPA (AMG-890) Agreement | Amgen                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Cash received as due under collaboration agreement   $ 30,000,000            
Deferred revenue   $ 30,000,000   0     0  
Deferred revenue amortized into revenue         $ 2,700,000 7,800,000   11,500,000
ARO-LPA (AMG-890) and ARO-AMG-1 Agreement | Amgen                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Revenue generated from work orders       $ 30,000   $ 600,000 $ 200,000 $ 600,000
Common Stock Purchase Agreement | Amgen                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Agreement date Sep. 28, 2016              
Shares issued | shares 3,002,793              
Stock issued, price per share | $ / shares $ 7.16              
Common Stock Purchase Agreement | Amgen | NASDAQ                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Number of trading days, used to calculate weighted average price of Common Stock, listed in stock market 30 days